Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNPH1 | O43598 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.38 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.37 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.37 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.36 |
| ▸ | CDK1 | P06493 | 4/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.36 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.36 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5083620 | 0.89 | CCNB2 (0.39) | DNPH1HPRT1CCNB2CDK1CCNB1 | |
| SCHEMBL5086049 | 0.88 | NT5E (0.38) | HPRT1FGFR1SLC22A6SRC | |
| SCHEMBL5086065 | 0.87 | ABL1 (0.38) | DNPH1HPRT1CCNB2CDK1CCNB1 | |
| SCHEMBL5083530 | 0.86 | NT5E (0.41) | PMP22CYP1A2NFKB1THPO | |
| SCHEMBL5083618 | 0.86 | NT5E (0.40) | PMP22CYP1A2NFKB1THPO | |
| SCHEMBL5085944 | 0.85 | LMNA (0.42) | DNPH1HDAC1HDAC2CCNB2CDK1 | |
| SCHEMBL5085981 | 0.83 | HPRT1 (0.37) | HPRT1FGFR1SLC22A6LMNASMN1; SMN2 | |
| SCHEMBL6055298 | 0.79 | CCNB2 (0.34) | CCNB2CDK1CCNB1CCNB3MAPK1 | |
| SCHEMBL6055289 | 0.79 | CCNB2 (0.36) | CCNB2CDK1CCNB1CCNB3RAB9A | |
| SCHEMBL14175343 | 0.75 | CCNB2 (0.38) | HDAC1CCNB2CDK1CCNB1CCNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7388002-B2 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-20060122391-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122391-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | POLR2H, NSUN2, POLR2E | DNPH1 566/4885P2RX3 1818/4885P2RX4 2679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.